These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 29545276)

  • 1. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
    Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
    Li Y; Sun F; Zhang W
    Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid.
    Lee HH; Jo KW; Yim JJ; Jeon D; Kang H; Shim TS
    Int J Infect Dis; 2020 Sep; 98():478-485. PubMed ID: 32640367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia.
    Soedarsono S; Mertaniasih NM; Kusmiati T; Permatasari A; Subay S; Adiono SH
    Int J Mycobacteriol; 2024 Apr; 13(2):140-146. PubMed ID: 38916383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
    Kempker RR; Mikiashvili L; Zhao Y; Benkeser D; Barbakadze K; Bablishvili N; Avaliani Z; Peloquin CA; Blumberg HM; Kipiani M
    Clin Infect Dis; 2020 Dec; 71(9):2336-2344. PubMed ID: 31712809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.
    Guglielmetti L; Barkane L; Le Dû D; Marigot-Outtandy D; Robert J; Veziris N; Yazdanpanah Y; Kuksa L; Caumes E; Fréchet-Jachym M
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29419439
    [No Abstract]   [Full Text] [Related]  

  • 12. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
    Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
    Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
    [No Abstract]   [Full Text] [Related]  

  • 13. Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.
    Mok J; Kang H; Hwang SH; Park JS; Kang B; Lee T; Koh WJ; Yim JJ; Jeon D
    J Antimicrob Chemother; 2018 Feb; 73(2):503-508. PubMed ID: 29069496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort.
    Koirala S; Borisov S; Danila E; Mariandyshev A; Shrestha B; Lukhele N; Dalcolmo M; Shakya SR; Miliauskas S; Kuksa L; Manga S; Aleksa A; Denholm JT; Khadka HB; Skrahina A; Diktanas S; Ferrarese M; Bruchfeld J; Koleva A; Piubello A; Koirala GS; Udwadia ZF; Palmero DJ; Munoz-Torrico M; Gc R; Gualano G; Grecu VI; Motta I; Papavasileiou A; Li Y; Hoefsloot W; Kunst H; Mazza-Stalder J; Payen MC; Akkerman OW; Bernal E; Manfrin V; Matteelli A; Mustafa Hamdan H; Nieto Marcos M; Cadiñanos Loidi J; Cebrian Gallardo JJ; Duarte R; Escobar Salinas N; Gomez Rosso R; Laniado-Laborín R; Martínez Robles E; Quirós Fernandez S; Rendon A; Solovic I; Tadolini M; Viggiani P; Belilovski E; Boeree MJ; Cai Q; Davidavičienė E; Forsman LD; De Los Rios J; Drakšienė J; Duga A; Elamin SE; Filippov A; Garcia A; Gaudiesiute I; Gavazova B; Gayoso R; Gruslys V; Jonsson J; Khimova E; Madonsela G; Magis-Escurra C; Marchese V; Matei M; Moschos C; Nakčerienė B; Nicod L; Palmieri F; Pontarelli A; Šmite A; Souleymane MB; Vescovo M; Zablockis R; Zhurkin D; Alffenaar JW; Caminero JA; Codecasa LR; García-García JM; Esposito S; Saderi L; Spanevello A; Visca D; Tiberi S; Pontali E; Centis R; D'Ambrosio L; van den Boom M; Sotgiu G; Migliori GB
    Pulmonology; 2021; 27(5):403-412. PubMed ID: 33753021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
    Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
    Mikiashvili L; Kempker RR; Chakhaia TS; Bablishvili N; Avaliani Z; Lomtadze N; Schechter MC; Kipiani M
    Clin Infect Dis; 2024 Apr; 78(4):1043-1052. PubMed ID: 37962987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?
    Cox V; Furin J
    Int J Tuberc Lung Dis; 2017 Dec; 21(12):1211-1213. PubMed ID: 29297439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.
    Solodovnikova V; Kumar AMV; Hurevich H; Sereda Y; Auchynka V; Katovich D; Klimuk D; Skrahin A; Setkina S; Charnysh I; Yedilbayev A; Skrahina A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.